A Study on Diagnosis and Treatment Strategies for Atlantoaxial Dislocation
Launched by PEKING UNIVERSITY THIRD HOSPITAL · Jan 22, 2024
Trial Information
Current as of May 18, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding the best ways to diagnose and treat a condition called atlantoaxial dislocation, which affects the top two bones in the neck. The main goal is to find out which surgical methods work best for different levels of dislocation severity, as current treatment choices often depend on individual surgeon experience rather than solid research. The study will gather information from a large group of patients who have had surgery for this condition and will track their progress over time to ensure the treatments are safe and effective.
To participate in this study, patients must be diagnosed with atlantoaxial dislocation and have undergone surgical treatment for it. The study is open to individuals of all ages and genders. By taking part, patients can expect to contribute to important research that aims to establish clearer guidelines for treating this condition, which could help improve outcomes for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients diagnosed with atlantoaxial dislocation and treated with surgery
- Exclusion Criteria:
- • Disagree to participate in this study.
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported